News | February 25, 2026
FDA greenlights Biocon’s Liraglutide for chronic weight management
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Under the deal, Quiver will receive an undisclosed advance payment and research support
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
If approved, DTX401 would be the first treatment to address the disease at its root cause
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
Subscribe To Our Newsletter & Stay Updated
